 Zhiying You
Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 14 | 2023 | 589 | 1.440 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 9 | 2023 | 209 | 1.350 |
Why?
| | Acute Kidney Injury | 7 | 2023 | 709 | 0.810 |
Why?
| | Endothelium, Vascular | 6 | 2021 | 907 | 0.660 |
Why?
| | Kidney Failure, Chronic | 6 | 2023 | 516 | 0.640 |
Why?
| | Kidney | 10 | 2022 | 1353 | 0.560 |
Why?
| | Vascular Stiffness | 4 | 2021 | 425 | 0.540 |
Why?
| | Glomerular Filtration Rate | 11 | 2023 | 683 | 0.490 |
Why?
| | Hypertension | 5 | 2021 | 1203 | 0.400 |
Why?
| | Blood Pressure | 5 | 2021 | 1664 | 0.400 |
Why?
| | Complement System Proteins | 4 | 2022 | 294 | 0.390 |
Why?
| | Cardiovascular Diseases | 4 | 2023 | 1798 | 0.370 |
Why?
| | Complement Factor B | 2 | 2023 | 102 | 0.360 |
Why?
| | Fibroblast Growth Factors | 3 | 2020 | 175 | 0.360 |
Why?
| | Brachial Artery | 3 | 2020 | 181 | 0.340 |
Why?
| | Chronic Kidney Disease-Mineral and Bone Disorder | 2 | 2018 | 11 | 0.320 |
Why?
| | Creatinine | 2 | 2020 | 491 | 0.310 |
Why?
| | Sodium | 2 | 2019 | 200 | 0.310 |
Why?
| | Double-Blind Method | 9 | 2023 | 1687 | 0.300 |
Why?
| | Vasodilation | 3 | 2020 | 457 | 0.300 |
Why?
| | Critical Illness | 3 | 2023 | 662 | 0.290 |
Why?
| | Endothelial Cells | 3 | 2021 | 732 | 0.290 |
Why?
| | Uric Acid | 2 | 2021 | 354 | 0.280 |
Why?
| | Cognition | 4 | 2023 | 1024 | 0.280 |
Why?
| | Prospective Studies | 13 | 2023 | 6471 | 0.280 |
Why?
| | Kidney Diseases | 2 | 2022 | 439 | 0.270 |
Why?
| | Kidney Transplantation | 4 | 2019 | 585 | 0.260 |
Why?
| | Renal Dialysis | 2 | 2019 | 378 | 0.250 |
Why?
| | Bicarbonates | 2 | 2023 | 44 | 0.240 |
Why?
| | Middle Aged | 23 | 2022 | 27617 | 0.240 |
Why?
| | Male | 32 | 2023 | 57801 | 0.230 |
Why?
| | Cognitive Dysfunction | 2 | 2018 | 301 | 0.230 |
Why?
| | Aged | 19 | 2022 | 19657 | 0.230 |
Why?
| | Pregnancy Complications | 2 | 2018 | 448 | 0.230 |
Why?
| | Sodium Bicarbonate | 2 | 2023 | 45 | 0.220 |
Why?
| | Humans | 44 | 2023 | 118974 | 0.220 |
Why?
| | Female | 31 | 2023 | 61565 | 0.210 |
Why?
| | Ferric Compounds | 1 | 2022 | 39 | 0.210 |
Why?
| | Sucrose | 1 | 2022 | 104 | 0.210 |
Why?
| | Complement Factor H | 1 | 2022 | 61 | 0.210 |
Why?
| | Cardiovascular System | 1 | 2023 | 127 | 0.210 |
Why?
| | Complement Pathway, Classical | 1 | 2021 | 19 | 0.200 |
Why?
| | Curcumin | 1 | 2021 | 33 | 0.200 |
Why?
| | Breathing Exercises | 1 | 2021 | 22 | 0.200 |
Why?
| | Inhalation | 1 | 2021 | 27 | 0.200 |
Why?
| | Nephrotic Syndrome | 1 | 2021 | 33 | 0.200 |
Why?
| | Biomarkers | 9 | 2023 | 3588 | 0.200 |
Why?
| | Nephrosis, Lipoid | 1 | 2021 | 31 | 0.200 |
Why?
| | Respiratory Muscles | 1 | 2021 | 36 | 0.200 |
Why?
| | Carcinoma, Basal Cell | 1 | 2022 | 67 | 0.200 |
Why?
| | Disease Progression | 7 | 2023 | 2490 | 0.200 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2021 | 39 | 0.200 |
Why?
| | Peritoneal Dialysis | 1 | 2022 | 84 | 0.200 |
Why?
| | Cardiolipins | 1 | 2021 | 73 | 0.190 |
Why?
| | Kidney Glomerulus | 1 | 2021 | 133 | 0.190 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2021 | 95 | 0.190 |
Why?
| | Adult | 19 | 2023 | 31512 | 0.190 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2020 | 36 | 0.190 |
Why?
| | Immunoglobulin M | 1 | 2021 | 253 | 0.180 |
Why?
| | Allopurinol | 2 | 2018 | 82 | 0.180 |
Why?
| | Bone Diseases | 1 | 2020 | 59 | 0.180 |
Why?
| | Lipocalins | 1 | 2019 | 38 | 0.180 |
Why?
| | Antigen-Antibody Complex | 1 | 2019 | 90 | 0.180 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 387 | 0.180 |
Why?
| | Complement C3d | 1 | 2019 | 60 | 0.180 |
Why?
| | Epitopes | 1 | 2021 | 443 | 0.170 |
Why?
| | Spironolactone | 1 | 2019 | 34 | 0.170 |
Why?
| | Renal Replacement Therapy | 1 | 2019 | 70 | 0.170 |
Why?
| | Vascular System Injuries | 1 | 2019 | 70 | 0.170 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 46 | 0.170 |
Why?
| | Vascular Diseases | 1 | 2021 | 241 | 0.170 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2018 | 38 | 0.170 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2018 | 68 | 0.160 |
Why?
| | Gene Amplification | 1 | 2018 | 97 | 0.160 |
Why?
| | Accidental Falls | 1 | 2020 | 154 | 0.160 |
Why?
| | Complement Factor D | 1 | 2018 | 28 | 0.160 |
Why?
| | Regional Blood Flow | 1 | 2020 | 418 | 0.160 |
Why?
| | Infant Mortality | 1 | 2018 | 94 | 0.160 |
Why?
| | Frailty | 1 | 2020 | 116 | 0.160 |
Why?
| | Potassium, Dietary | 1 | 2018 | 11 | 0.160 |
Why?
| | Infant, Low Birth Weight | 1 | 2018 | 125 | 0.160 |
Why?
| | Propensity Score | 1 | 2019 | 242 | 0.160 |
Why?
| | Complement Activation | 4 | 2022 | 350 | 0.160 |
Why?
| | Metformin | 1 | 2021 | 295 | 0.160 |
Why?
| | Sodium, Dietary | 1 | 2018 | 43 | 0.150 |
Why?
| | Hyponatremia | 1 | 2018 | 42 | 0.150 |
Why?
| | Acidosis | 1 | 2018 | 86 | 0.150 |
Why?
| | Cell-Derived Microparticles | 1 | 2018 | 62 | 0.150 |
Why?
| | Antibodies | 1 | 2019 | 392 | 0.150 |
Why?
| | Death | 1 | 2018 | 105 | 0.150 |
Why?
| | Blood Vessels | 1 | 2019 | 187 | 0.150 |
Why?
| | Complement Pathway, Alternative | 1 | 2018 | 117 | 0.150 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2019 | 227 | 0.150 |
Why?
| | Calcitriol | 1 | 2017 | 55 | 0.150 |
Why?
| | Cholecalciferol | 1 | 2017 | 51 | 0.150 |
Why?
| | Thrombocytopenia | 1 | 2019 | 185 | 0.150 |
Why?
| | Fructose | 1 | 2018 | 204 | 0.150 |
Why?
| | Vascular Calcification | 1 | 2018 | 123 | 0.140 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2018 | 185 | 0.140 |
Why?
| | Pre-Eclampsia | 1 | 2018 | 183 | 0.140 |
Why?
| | Living Donors | 1 | 2018 | 319 | 0.140 |
Why?
| | Nitric Oxide | 1 | 2021 | 892 | 0.140 |
Why?
| | Peripheral Arterial Disease | 1 | 2021 | 377 | 0.130 |
Why?
| | Glioma | 1 | 2018 | 306 | 0.130 |
Why?
| | Skin Neoplasms | 1 | 2022 | 762 | 0.130 |
Why?
| | Hyperuricemia | 1 | 2016 | 134 | 0.130 |
Why?
| | Oxidative Stress | 1 | 2021 | 1178 | 0.130 |
Why?
| | Myocardial Infarction | 1 | 2022 | 968 | 0.130 |
Why?
| | Recombinant Fusion Proteins | 1 | 2017 | 653 | 0.120 |
Why?
| | Dietary Supplements | 1 | 2017 | 467 | 0.120 |
Why?
| | Longitudinal Studies | 5 | 2020 | 2513 | 0.120 |
Why?
| | Risk Factors | 7 | 2022 | 9000 | 0.120 |
Why?
| | Interleukin-1 | 1 | 2017 | 980 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 827 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2017 | 496 | 0.110 |
Why?
| | Case-Control Studies | 4 | 2021 | 3171 | 0.100 |
Why?
| | Time Factors | 5 | 2021 | 6412 | 0.100 |
Why?
| | Health Services Accessibility | 1 | 2017 | 781 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2019 | 4596 | 0.100 |
Why?
| | Pulse Wave Analysis | 2 | 2023 | 216 | 0.100 |
Why?
| | Tooth Loss | 1 | 2011 | 30 | 0.100 |
Why?
| | Pilot Projects | 3 | 2022 | 1419 | 0.100 |
Why?
| | Young Adult | 6 | 2023 | 10793 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2018 | 1022 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 1244 | 0.090 |
Why?
| | Severity of Illness Index | 4 | 2020 | 2674 | 0.090 |
Why?
| | Liver | 1 | 2018 | 1816 | 0.090 |
Why?
| | Vitamin D | 3 | 2018 | 354 | 0.090 |
Why?
| | Risk Assessment | 4 | 2021 | 3057 | 0.090 |
Why?
| | Prognosis | 3 | 2021 | 3443 | 0.080 |
Why?
| | Nutritional Status | 2 | 2022 | 300 | 0.080 |
Why?
| | Cross-Sectional Studies | 4 | 2020 | 4552 | 0.080 |
Why?
| | Mice | 5 | 2022 | 15520 | 0.080 |
Why?
| | Parathyroid Hormone | 2 | 2018 | 99 | 0.080 |
Why?
| | Self Report | 1 | 2011 | 699 | 0.070 |
Why?
| | Independent Living | 2 | 2018 | 86 | 0.070 |
Why?
| | Intensive Care Units | 2 | 2021 | 635 | 0.070 |
Why?
| | Brain | 1 | 2018 | 2490 | 0.070 |
Why?
| | Child | 5 | 2023 | 19129 | 0.070 |
Why?
| | Pregnancy Outcome | 2 | 2018 | 349 | 0.070 |
Why?
| | Inflammation Mediators | 2 | 2019 | 502 | 0.070 |
Why?
| | Animals | 6 | 2022 | 33381 | 0.060 |
Why?
| | Obesity | 1 | 2017 | 2746 | 0.060 |
Why?
| | Pravastatin | 1 | 2023 | 29 | 0.060 |
Why?
| | United States | 5 | 2019 | 12555 | 0.060 |
Why?
| | Incidence | 2 | 2021 | 2424 | 0.060 |
Why?
| | Sex Factors | 2 | 2020 | 1781 | 0.060 |
Why?
| | Plant Proteins | 1 | 2023 | 81 | 0.060 |
Why?
| | Patched-1 Receptor | 1 | 2022 | 15 | 0.050 |
Why?
| | Hyperphosphatemia | 1 | 2022 | 14 | 0.050 |
Why?
| | Hypoalbuminemia | 1 | 2022 | 27 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2021 | 4077 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2023 | 233 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2021 | 9342 | 0.050 |
Why?
| | Phosphorus | 1 | 2022 | 84 | 0.050 |
Why?
| | Serum Albumin | 1 | 2022 | 146 | 0.050 |
Why?
| | Cohort Studies | 3 | 2018 | 5116 | 0.050 |
Why?
| | Drug Combinations | 1 | 2022 | 291 | 0.050 |
Why?
| | Gonadal Steroid Hormones | 1 | 2022 | 122 | 0.050 |
Why?
| | Phosphates | 1 | 2022 | 167 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2022 | 305 | 0.050 |
Why?
| | Antibody Specificity | 1 | 2021 | 184 | 0.050 |
Why?
| | Prevalence | 2 | 2018 | 2326 | 0.050 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 175 | 0.050 |
Why?
| | Minerals | 1 | 2020 | 39 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2018 | 6561 | 0.050 |
Why?
| | Lymphocytes | 1 | 2022 | 347 | 0.050 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2019 | 39 | 0.050 |
Why?
| | Acute-Phase Proteins | 1 | 2019 | 67 | 0.040 |
Why?
| | Lipocalin-2 | 1 | 2019 | 64 | 0.040 |
Why?
| | Colorado | 2 | 2021 | 4196 | 0.040 |
Why?
| | Matched-Pair Analysis | 1 | 2019 | 39 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2022 | 381 | 0.040 |
Why?
| | Allografts | 1 | 2019 | 135 | 0.040 |
Why?
| | Testosterone | 1 | 2022 | 351 | 0.040 |
Why?
| | Monocytes | 1 | 2022 | 513 | 0.040 |
Why?
| | Complement C4a | 1 | 2018 | 7 | 0.040 |
Why?
| | Half-Life | 1 | 2018 | 147 | 0.040 |
Why?
| | Biological Availability | 1 | 2018 | 126 | 0.040 |
Why?
| | Hepatocytes | 1 | 2019 | 205 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2021 | 749 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 170 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2023 | 671 | 0.040 |
Why?
| | Complement C5a | 1 | 2018 | 60 | 0.040 |
Why?
| | Complement Membrane Attack Complex | 1 | 2018 | 35 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2019 | 415 | 0.040 |
Why?
| | Clone Cells | 1 | 2018 | 248 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 2018 | 136 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 253 | 0.040 |
Why?
| | Fathers | 1 | 2018 | 47 | 0.040 |
Why?
| | Healthy Aging | 1 | 2018 | 18 | 0.040 |
Why?
| | Area Under Curve | 1 | 2018 | 296 | 0.040 |
Why?
| | TRPP Cation Channels | 1 | 2018 | 63 | 0.040 |
Why?
| | Ligands | 1 | 2019 | 567 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2018 | 399 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2021 | 681 | 0.040 |
Why?
| | ROC Curve | 1 | 2018 | 473 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2018 | 456 | 0.040 |
Why?
| | Body Mass Index | 2 | 2017 | 2092 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2018 | 5255 | 0.040 |
Why?
| | Adolescent | 3 | 2021 | 18480 | 0.040 |
Why?
| | Organ Size | 1 | 2017 | 460 | 0.040 |
Why?
| | Congenital Abnormalities | 1 | 2017 | 74 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2018 | 3174 | 0.040 |
Why?
| | Administration, Oral | 1 | 2018 | 756 | 0.040 |
Why?
| | Graft Rejection | 1 | 2019 | 555 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 2018 | 204 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1079 | 0.030 |
Why?
| | Waiting Lists | 1 | 2017 | 228 | 0.030 |
Why?
| | Pregnancy | 2 | 2018 | 5691 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1267 | 0.030 |
Why?
| | Up-Regulation | 1 | 2019 | 872 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2019 | 688 | 0.030 |
Why?
| | Neuroimaging | 1 | 2018 | 256 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2019 | 788 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 842 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1868 | 0.030 |
Why?
| | Protein Binding | 1 | 2019 | 1975 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2018 | 531 | 0.030 |
Why?
| | Autoimmunity | 1 | 2019 | 831 | 0.030 |
Why?
| | Survival Rate | 1 | 2018 | 1720 | 0.030 |
Why?
| | Overweight | 1 | 2017 | 502 | 0.030 |
Why?
| | Premature Birth | 1 | 2017 | 284 | 0.030 |
Why?
| | Recovery of Function | 1 | 2017 | 604 | 0.030 |
Why?
| | Glucose | 1 | 2018 | 953 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2019 | 2680 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2018 | 1032 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2019 | 1284 | 0.030 |
Why?
| | Age Factors | 1 | 2020 | 2995 | 0.030 |
Why?
| | Genotype | 1 | 2018 | 1882 | 0.030 |
Why?
| | Proteomics | 1 | 2018 | 876 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2020 | 12978 | 0.030 |
Why?
| | Autoantibodies | 1 | 2019 | 1335 | 0.030 |
Why?
| | Mothers | 1 | 2018 | 682 | 0.030 |
Why?
| | Cytokines | 1 | 2019 | 1900 | 0.030 |
Why?
| | Hyperlipidemias | 1 | 2011 | 128 | 0.020 |
Why?
| | Income | 1 | 2011 | 173 | 0.020 |
Why?
| | Rats | 1 | 2018 | 5392 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 3730 | 0.020 |
Why?
| | Mental Recall | 1 | 2011 | 180 | 0.020 |
Why?
| | Social Class | 1 | 2011 | 218 | 0.020 |
Why?
| | Blood Glucose | 1 | 2018 | 1939 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2011 | 360 | 0.020 |
Why?
| | Educational Status | 1 | 2011 | 437 | 0.020 |
Why?
| | Learning | 1 | 2011 | 374 | 0.020 |
Why?
| | Infant | 1 | 2018 | 8293 | 0.020 |
Why?
| | Smoking | 1 | 2011 | 1487 | 0.010 |
Why?
| | Depression | 1 | 2011 | 1132 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2011 | 942 | 0.010 |
Why?
| | Stroke | 1 | 2011 | 1047 | 0.010 |
Why?
|
|
You's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|